Business Wire

CA-GLOBALLOGIC

8.4.2024 14:38:30 CEST | Business Wire | Press release

Share
GlobalLogic Announces ‘Platform of Platforms’ for Enabling Enterprise-Grade AI

GlobalLogic, a Hitachi group company, today announced a first-of-its-kind Platform-of-Platforms architecture designed to support deployment of enterprise-grade artificial intelligence (AI). GlobalLogic has designed the architecture to address the critical challenges every enterprise must overcome when operationalizing AI and generative AI (GenAI) at scale.

To realize the potential that AI promises, enterprises must address data privacy and security requirements, prevent intellectual property (IP) leakage and manage legal risks. They also need to identify an approach that allows for technical agility as new models, platforms and other innovations take shape. At the same time, leaders must manage organizational change and find effective strategies for controlling costs and driving return on AI/GenAI investments.

With over a decade of experience in delivering and deploying AI in software products and enterprise platforms, GlobalLogic offers a unique perspective on the design, data and engineering challenges of enterprise-grade, production-ready AI and GenAI. Created in partnership with leading hyperscalers and leveraging their foundational GenAI capabilities, GlobalLogic’s architecture is the first of its kind for unifying and industrializing enterprise-grade AI and GenAI solutions.

GlobalLogic identifies responsibility, reliability and reusability as key to enterprise-grade AI

“As companies work to move from AI and GenAI prototypes to enterprise-scale deployments, it has become clear that using this technology requires far more than sending prompts to a large language model (LLM),” said Sumit Sood, COO and Head of Engineering, GlobalLogic. “We have been helping enterprises adopt GenAI since 2021 and ‘traditional’ AI for much longer, often in life-critical situations. We understand what needs to be done to ensure responsibility, reliability and reusability in AI platforms.”

Sood explains that the responsibility tenet focuses on the goal of offering responses that are accurate, lawful and in compliance with security and governance requirements. The reliability tenet requires mechanisms for correcting model drift, hallucinations and security threats over time. Finally, the reusability tenet is crucial to implementing common data ingestion, preparation and model training and shared consumption mechanisms – which help contain costs and mitigate risk by preventing duplicative work.

GlobalLogic’s AI Platform-of-Platforms architecture addresses critical needs related to observability, security, governance and consumption. It makes it possible to integrate best-of-breed models, algorithms and solutions whether deployed in the cloud or on premises. It also includes accelerators for rapidly deploying some of the most sought-after use cases, including customer support and operations, software development and legacy migration, and enterprise knowledge management.

“The GenAI landscape is highly dynamic,” Sood said. “In an environment where the ‘best’ technology can change month to month or even week to week, GlobalLogic’s Platform-of-Platforms approach lets our clients pick the winners to deliver the best enterprise-class GenAI to support their business outcomes.”

To learn more about GlobalLogic’s AI solutions and advisory capabilities, visit www.globallogic.com/services/offerings/generative-ai/.

ABOUT GLOBALLOGIC

GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408417447/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye

Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse

Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk

Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release

For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye